Clinical and Translational Oncology

, Volume 21, Issue 5, pp 630–635 | Cite as

Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood

  • P. H. P. Liberman
  • M. V. S. Goffi-GomezEmail author
  • C. Schultz
  • P. L. Jacob
  • C. A. A. de Paula
  • E. L. Sartorato
  • G. T. Torrezan
  • E. N. Ferreira
  • D. M. Carraro
Research Article


Background and aim

Ototoxicity is a potential adverse effect of chemotherapy with platin drugs, such as cisplatin and carboplatin, in children. Hearing loss (HL) affecting frequencies below 4 kHz can compromise speech perception. The aim of this study was to investigate whether genetic variants previously implicated in ototoxicity are associated with HL overall and HL below 4 kHz in pediatric oncology patients treated with cisplatin or carboplatin.

Materials and methods

Patients given cisplatin or carboplatin for a pediatric cancer at least 5 years prior to the start of the study were enrolled. The patients underwent comprehensive audiological evaluations and genotyping to detect the presence of the GJB2 c.35delG, GSTP1 c.313A>G, and MT-RNR1 m.1555A>G polymorphisms.


HL was identified in 31/61 patients (50.8%), including 28/42 treated with cisplatin (66.6%) and 3/19 treated with carboplatin (15.8%). HL was associated with higher mean doses of cisplatin (p = .002) and carboplatin (p = .010). The c.313A>G variant of GSTP1 (heterozygous or homozygous) was detected in 31/61 patients (50.8%). An association between this variant allele and HL involving frequencies ≤ 4 kHz was identified (p = .020; 10-fold vs. non-carriers). No associations with HL were observed for GJB2 or MT-RNR1 gene variants.


The GSTP1 c.313A>G variant may increase the risk of low-frequency HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy.


Hearing loss Cancer Ototoxicity Cisplatin Carboplatin GSTP1 



The authors would like to acknowledge Dr. Sami Liberman and Vinicius Calsavara for their support on the statistical analysis.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts to declare.

Ethical approval

This research involved human participants and it was approved by the Ethics Committee of Hospital AC Camargo Cancer Center under the protocol

Informed consent

Patients signed its informed consent.


  1. 1.
    Brock PR, Yeomans EC, Bellman SC, Pritchard J. Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer Suppl. 1992;18:S36–40.Google Scholar
  2. 2.
    Skinner R. Best practice in assessing ototoxicity in children with cancer. Eur J Cancer. 2004;40:2352–4.CrossRefGoogle Scholar
  3. 3.
    Schultz C, Goffi-Gomez MVS, Liberman PHP, Pellizzon AC, Carvalho AL. Hearing loss and complaint in patients with head and neck cancer treated with radiotherapy. Arch Otolaryngol Head Neck Surg. 2010;136(1):1065–9. Scholar
  4. 4.
    Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, Heinecke A, Horst J, Jürgens H, Lamprecht-Dinnesen A. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000;11:639–43.CrossRefGoogle Scholar
  5. 5.
    Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tonoku J Exp Med. 2009;219:177–86.CrossRefGoogle Scholar
  6. 6.
    Mukherjea D, Rybak LP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics. 2011;12(7):1039–50. Scholar
  7. 7.
    Hyppolito MA, Oliveira JAA. Ototoxicity, otoprotection and self defense of the coclear outer hair cells. Medicina (Ribeirão Preto). 2005;38:279–89.CrossRefGoogle Scholar
  8. 8.
    Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458–69. Scholar
  9. 9.
    Knoll C, Smith RJ, Shores C, Blatt J. Hearing genes and cisplatin deafness: a pilot study. Laryngoscope. 2006;116:72–4.CrossRefGoogle Scholar
  10. 10.
    Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007;226(1–2):157–67.CrossRefGoogle Scholar
  11. 11.
    Sabatini LM, Mathews C, Ptak D, Doshi S, Tynan K, Hegde MR, Burke TL, Bossler AD. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. J Mol Diagn. 2016;18(3):319–28.CrossRefGoogle Scholar
  12. 12.
    Peters U, Preisler-Adams S, Lanvers-Kaminsky C, Jürgens H, Lamprecht-Dinnesen A. Sequence variations of mitochondrial DNA and individual sensitivity to theototoxic effect of cisplatin. Anticancer Res. 2003;23:1249–55.Google Scholar
  13. 13.
    Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet. 2000;9:1787–93.CrossRefGoogle Scholar
  14. 14.
    el Barbary A, Altschuler RA, Schacht J. Gluthathione S-transferases in the organ of corti of the rat: enzymatic activity, subunit composition and immunohistochemical localization. Hear Res. 1993;71:80–90.CrossRefGoogle Scholar
  15. 15.
    Hu X, Xia H, Srivastava SK, Pal A, Awasthi YC, Zimniak P, Singh SV. Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c] phenan-threne and benzo[g]chrysene. Cancer Res. 1998;58:5340–3.Google Scholar
  16. 16.
    Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput K, Sullivan M, Neuwelt EA. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408–17. Scholar
  17. 17.
    Liberman PHP, Goffi-Gomez MVS, Schultz C, Lopes LF. What are the audiometric frequencies affected are the responsible for the hearing complaint in the hearing loss for ototoxicity after the oncological treatment? Arq Int Otorrinolaringol. 2012;16:26–31.Google Scholar
  18. 18.
    Liberman PH, Schultz C, Goffi-Gomez MV, Lopes LF. Speech recognition and frequency of hearing loss in patients treated for cancer in childhood. Pediatr Blood Cancer. 2013;60(10):1709–13. Scholar
  19. 19.
    Friedman TB, Griffith AJ. Human nonsyndromic sensori-neural deafness. Ann Rev Genom Hum Genet. 2003;4:341–402.CrossRefGoogle Scholar
  20. 20.
    Iwasaki S, Tamagawa Y, Ocho S, Hoshino T, Kitamura K. Hereditary sensorineural hearing loss of unknown cause involving mitochondrial DNA A1555 mutation. ORL J Otorhinolaryngol Relat Spec. 2000;62:100–3.CrossRefGoogle Scholar
  21. 21.
    Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis (Lond). 1997;18:641–4.CrossRefGoogle Scholar
  22. 22.
    Jerónimo C, Varzim G, Henrique R, Oliveira J, Bento MJ, Silva C, Lopes C, Sidransky D. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomark Prev. 2002;11(5):445–50.Google Scholar
  23. 23.
    Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Aerts I, Mercier G, Bours D, Desjardins L, Doz F. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52(5):637–43. Scholar
  24. 24.
    Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, Haik BG, Wilson MW, Rodriguez-Galindo C. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012;30(10):1034–41. Scholar
  25. 25.
    Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012;59:144–8. Scholar
  26. 26.
    Peleva E, Emami N, Alzahrani M, Bezdjian A, Gurberg J, Carret AS, Daniel SJ. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer. 2014;61(11):2012–7. Scholar
  27. 27.
    Estivill X, Govea N, Barceló E, Badenas C, Romero E, Moral L, Scozzri R, D’Urbano L, Zeviani M, Torroni A. Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet. 1998;62(1):27–35.CrossRefGoogle Scholar
  28. 28.
    ABraOM: Brazilian genomic variants.
  29. 29.
    Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25:708–14.CrossRefGoogle Scholar
  30. 30.
    Rednam S, Scheurer ME, Adesina A, Lau CC, Okcu MF. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma. Pediatr Blood Cancer. 2013;60:593–8. Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  • P. H. P. Liberman
    • 1
  • M. V. S. Goffi-Gomez
    • 1
    Email author
  • C. Schultz
    • 1
  • P. L. Jacob
    • 2
  • C. A. A. de Paula
    • 3
  • E. L. Sartorato
    • 2
  • G. T. Torrezan
    • 3
  • E. N. Ferreira
    • 3
  • D. M. Carraro
    • 3
  1. 1.Audiology DepartmentAC Camargo Cancer CenterSão PauloBrazil
  2. 2.Human Molecular Genetics Laboratory, Molecular Biology and Genetic Engineering Center, CBMEGState University of Campinas (UNICAMP)CampinasBrazil
  3. 3.Genomics and Molecular Biology Laboratory, International Research Center/CIPEAC Camargo Cancer CenterSão PauloBrazil

Personalised recommendations